Swipe om te navigeren naar een ander artikel
Sporadic desmoid-type fibromatosis (DTF) is a rare, chronic, non-metastasising, disease of the soft tissues. It is characterised by local invasive and unpredictable growth behaviour and a high propensity of local recurrence after surgery thereby often having a great impact on health-related quality of life (HRQL). This study aims to review currently used HRQL measures and to asses HRQL issues among DTF patients.
A mixed methods methodology was used consisting of (1) a systematic literature review, according to the PRISMA guidelines (2009), using search terms related to sporadic DTF and HRQL in commonly used databases (e.g. Embase, Medline Ovid, Web of science, Cochrane Central, Psyc Info, and Google scholar), to provide an overview of measures previously used to evaluate HRQL among DTF patients; (2) focus groups to gain insight into HRQL issues experienced by DTF patients.
The search strategy identified thirteen articles reporting HRQL measures using a wide variety of cancer-specific HRQL tools, functional scores, symptom scales (e.g. NRS), and single-item outcomes (e.g. pain and functional impairment). No DTF-specific HRQL tool was found. Qualitative analysis of three focus groups (6 males, 9 females) showed that participants emphasised the negative impact of DTF and/or its treatment on several HRQL domains. Six themes were identified: (1) diagnosis, (2) treatment, (3) follow-up and recurrence, (4) physical domain, (5) psychological and emotional domain, and (6) social domain.
A DTF-specific HRQL tool and consensus regarding the preferred measurement tool among DTF patients is lacking. Our study indicates that HRQL of DTF patients was negatively affected in several domains. A DTF-specific HRQL measure could improve our understanding of short- and long-term effects and, ideally, can be used in both clinic and for research purposes.
World Health Organization (2016). International statistical classification of diseases and related health problems, 10th revision, volume 3.
van Broekhoven, D. L., et al. (2015). Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: A population-based study. Annals of Surgical Oncology, 22, 2817–2823. CrossRef
De Marchis, M. L., et al. (2017) Desmoid tumors in familial adenomatous polyposis. Anticancer Research, 37, 3357–3336.
Lips, D. J., et al. (2009). The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). European Journal of Surgical Oncology, 35, 3–10. CrossRef
Reitamo, J. J., et al. (1986). The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. The American Journal of Surgery, 151, 230–237. CrossRef
Mullen, J. T., et al. (2013). β-catenin mutation status and outcomes in sporadic desmoid tumors. The Oncologist, 18, 1043–1049. CrossRef
van Broekhoven, D. L., et al. (2015). Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Annals of Surgical Oncology, 22, 1464–1470. CrossRef
Fiore, M., et al. (2014). Desmoid-type fibromatosis and pregnancy: A multi-institutional analysis of recurrence and obstetric risk. Annals of Surgery, 259, 973–978. CrossRef
Sleijfer, S. (2009). Management of aggressive fibromatosis: Can we unravel the maze of treatment options? European Journal of Cancer, 45, 2928–2929. CrossRef
Colombo, C., et al. (2015) Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. European Journal of Cancer, 51, 186–192. CrossRef
Salas, S., et al. (2011). Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: A wait-and-see policy according to tumor presentation. Journal of Clinical Oncology, 29, 3553–3558. CrossRef
Al-Jazrawe, M., et al. (2015). Optimal therapy for desmoid tumors: Current options and challenges for the future. Expert Review of Anticancer Therapy, 15, 1443–1458. CrossRef
Penel, N., et al. (2017). Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. European Journal of Cancer, 83, 125–131. CrossRef
van Broekhoven, D. L., et al. (2016). Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. BMC Cancer, 16, 686. CrossRef
Landelijke Richtlijn Wekedelen Tumoren, versie 2.0 (2011). Oncoline, richtlijnen oncologische zorg; 2011.
Bonvalot, S., et al. (2013). Spontaneous regression of primary abdominal wall desmoid tumors: More common than previously thought. Annals of Surgical Oncology, 20, 4096–4102. CrossRef
Peng, P. D., et al. (2012). Management and recurrence patterns of desmoids tumors: A multi-institutional analysis of 211 patients. Annals of Surgical Oncology, 19, 4036–4042. CrossRef
Kasper, B., et al. (2017). Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). European Journal of Cancer, 76, 60–67. CrossRef
Bertani, E., et al. (2009). Desmoid tumors of the anterior abdominal wall: Results from a monocentric surgical experience and review of the literature. Annals of Surgical Oncology, 16, 1642–1649. CrossRef
Kasper, B., et al. (2017). An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncology, 28, 2399–2408. CrossRef
Marshall, S., et al. (2006). Impact of patient-reported outcome measures on routine practice: A structured review. Journal of Evaluation in Clinical Practice, 12, 559–568. CrossRef
Moher, D., et al. (2010). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. International Journal of Surgery, 8, 336–341. CrossRef
Beaton, D. E., et al. (2001). Measuring the whole or the parts? Validity, reliability, and responsiveness of the disabilities of the arm, shoulder and hand outcome measure in different regions of the upper extremity. Journal of Hand Therapy, 14, 128–146. CrossRef
Dhinsa, B. S., et al. (2014). The outcome of resection of the distal ulna for tumour without soft-tissue or prosthetic reconstruction. The Bone & Joint Journal, 96, 1392–1395. CrossRef
Hudak, P. L., et al. (1996). Development of an upper extremity outcome measure: The DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). American Journal of Industrial Medicine, 29, 602–608. CrossRef
Engelhardt, T. O., et al. (2008). About the self-reported quality of life after amputation of the hand in patients with upper extremity tumors. Handchirurgie Mikrochirurgie Plastische Chirurgie, 40, 23–30. CrossRef
Tang, F., et al. (2015). Large desmoid-type fibromatosis of the shoulder girdle: Operative approach selection and clinic outcome. International Orthopaedics, 39, 363–369. CrossRef
Gibbons, C. L., et al. (1998). Function after subtotal scapulectomy for neoplasm of bone and soft tissue. The Journal of Bone and Joint Surgery, 80, 38–42. CrossRef
Enneking, W. F., et al. (1993) A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clinical Orthopaedics and Related Research, 286, 241–246.
Goubier, J. N., et al. (2003). Desmoid tumors and brachial plexus. Chirurgie de la Main, 22, 203–206. CrossRef
Aaronson, N. K., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376. CrossRef
Kummar, S., et al. (2017). Clinical activity of the gamma-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). Journal of Clinical Oncology, 35, 1561–1569. CrossRef
Cleeland, C. S., et al. (2000). Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer, 89, 1634–1646. CrossRef
Catton, C. N., et al. (1995). Aggressive fibromatosis: Optimisation of local management with a retrospective failure analysis. Radiotherapy and Oncology, 34, 17–22. CrossRef
Johnstone, P. A., et al. (1994). Sarcomas of the hand and foot: Analysis of local control and functional result with combined modality therapy in extremity preservation. International Journal of Radiation Oncology Biology Physics, 29, 735–745. CrossRef
Hjermstad, M. J., et al. (2011). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: A systematic literature review. Journal of Pain and Symptom Management, 41, 1073–1093. CrossRef
Ghanouni, P., et al. (2017). Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: A retrospective multicenter study. European Radiology, 27, 732–740. CrossRef
Fiore, M., et al. (2011) Activity of toremifene in sporadic desmoid-type fibromatosis. Journal of Clinical Oncology, 29 10033. CrossRef
Davis, A. M., et al. (1996). Development of a measure of physical function for patients with bone and soft tissue sarcoma. Quality of Life Research, 5, 508–516. CrossRef
Willeumier, J. J., et al. (2017). Cross-cultural adaptation, translation, and validation of the toronto extremity salvage score for extremity bone and soft tissue tumor patients in Netherlands. Sarcoma, 2017, 6197525. CrossRef
Stoeckle, E., et al. (2009). A critical analysis of treatment strategies in desmoid tumours: A review of a series of 106 cases. European Journal of Surgical Oncology, 35, 129–134. CrossRef
Al-Otaibi, M. L., et al. (2008). Low-dose chemotherapy for extra-abdominal desmoid tumor. Saudi Medical Journal, 29, 1730–1734. PubMed
Hoos, A., et al. (2000) Desmoid tumors of the head and neck: A clinical study of a rare entity. Head and Neck, 22, 814–821. CrossRef
Tausch, A. P., & Menold, N. (2016). Methodological aspects of focus groups in health research: Results of qualitative interviews with focus group moderators. Global Qualitative Nursing Research, 3, 2333393616630466. CrossRef
The Desmoid Tumor Research Foundation (2017). DTRF patient registry.
Paty, J., et al. (2017). Prospective development of a patient reported outcomes (PRO) tool in desmoid tumors: A novel clinical trial endpoint. Journal of Clinical Oncology, 35, 11022. CrossRef
Johnson, C., et al. Guidelines for developing questionnaire modules. On Behalf of EORTC Quality of Life Group 2011.
- Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study
Milea J. M. Timbergen
Lonneke V. van de Poll-Franse
Dirk J. Grünhagen
Winette T. van der Graaf
- Springer International Publishing